hamburger-icon
close-icon

invest-iconInvest

trade-iconTrade

depository-iconTrading Platforms

depository-iconDepository

watch-iconWatch Markets

depository-iconFPI

watch-iconMerchant Banking

watch-iconInstitutional Broking

watch-iconMTF

partner-iconBecome a Partner

partner-iconKnowledge Center

watch-iconResearch

about-iconAbout Us

support-iconSupport

support-iconPricing

support-iconQuick Links

support-iconBlog

hamburger-icon
close-icon

Astrazeneca Pharma India Ltd

  • BSE Code : 506820
  • NSE Symbol : ASTRAZEN
  • ISIN : INE203A01020
  • Industry :PHARMACEUTICALS - MULTINATIONAL
Trade Now

up-arrow 10,509.50 314.50(3.08%)

Open Price (₹)

10,029.00

Prev. Close (₹)

10,195.00

Volume (No’s)

106,451

Market Cap (₹)

26,273.75

Low Price (₹)

9,961.00

High Price (₹)

10,691.00

 

Board Meetings

Start Date End Date Purpose
21-May-2025 30-May-2025 Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. The audited financial results of the Company for the quarter and year ended March 31 2025. 2. To recommend Dividend if any on the equity shares of the Company for the financial year 2024-25. We also inform you that the Trading Window remains closed for all Designated Persons from March 16 2025 to June 1 2025 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. Recommendation of Dividend for the Financial Year 2024-25 (As Per BSE Announcement Dated on :30.05.2025)
20-Jan-2025 11-Feb-2025 Quarterly Results ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve This is to inform that the Meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, February 11, 2025 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2024 to February 13, 2025 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. At the Board meeting of the Company held on Tuesday, February 11, 2025, the Board of Directors considered and approved the unaudited financial results of the Company for the quarter ended December 31, 2024. The said unaudited financial results together with the Limited Review Report of the Statutory Auditors dated December 31, 2024 are enclosed herewith. (As Per BSE Announcement dated on 11.02.2025) Please find the enclosed intimation of the Company as per the captioned subject. (As per BSE Announcement Dated on 03/03/2025)
25-Oct-2024 13-Nov-2024 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2024. Please find the enclosed financial results for the quarter and half year ended September 30, 2024. (As Per BSE Announcement dated on 13.11.2024)
24-Jul-2024 08-Aug-2024 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve The Unaudited Financial Results of the Company for the quarter ended June 30 2024. We would also like to inform you that the Trading Window remains closed for all Designated Persons from June 16 2024 to August 10 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Please find the enclosed financial results for the quarter ended June 30, 2024. (As per BSE Announcement Dated on 08/08/2024)
15-May-2024 27-May-2024 ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve 1. The Audited financial results of the Company for the quarter and year ended March 31 2024. 2. To recommend Dividend if any on the equity shares of the Company for the financial year 2023-24. We also inform you that the Trading Window remains closed for all Designated Persons from March 16 2024 to May 29 2024 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. We wish to inform that at the meeting of Board of Directors of the Company held on May 27, 2024, the Board has recommended dividend of Rs. 24/- per equity share of Rs. 2/- each subject to the approval of the shareholders at the forthcoming AGM of the Company. (As Per BSE Announcement Dated on 27/05/2024)

NIFTY:24,718.60  Up arrow
-169.60(-0.68%)
SENSEX:81,691.98  Up arrow
-573.38(-0.70%)

Product

Trading


Useful links

Who we are

Connect with us

Stay on top of the markets with our bite-sized newsletter delivered right to your Inbox!

footer-arrow-icon
appstore appstore

#1011 Solitaire Corporate Park, Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai - 400093.

Arihant Capital Markets Limited is a SEBI registered stock broker and depository participant. SEBI Registration number: INZ000180939, Member of NSE:07839; BSE :313; NSDL - IN-DP-127-2015 DP ID-IN301983; CDSL DP ID-43000; NCDEX - 01274; MCX - 56565; AMFI - ARN 15114; AMFI-registered Mutual Fund Distributor; ARN registration year - 2004; ARN validity up to- 18/12/2025; SEBI Merchant Banking Reg. No. - MB INM000011070; SEBI Research Analyst Reg. No. - INH000002764 (BSE RA Enlistment No. 5168) . Registered Address: 6, Lad colony, Y.N. Road, Indore – 452003. Corporate office address: #1011 Solitaire Corporate Park, Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai - 400093.

Please carefully read the risk disclosure document as prescribed by SEBI, as well as the 'Do’s and Don’ts' provided by NSE, BSE, NCDEX, and MCX. If you have any complaints related to securities broking, kindly contact us at complaint@arihantcapital.com. For DP-related matters, please reach out to us at depository@arihantcapital.com.

If you want to register your complaints through SEBI Score 2.0 Portal please click here. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances

Investments in securities market are subject to market risks; read all the related documents carefully before investing.

Disclaimer: Arihant Capital Markets Limited is engaged in client based and proprietary trading on various exchanges.

  • ATTENTION INVESTORS :
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • For Stock Broking Transaction 'Prevent unauthorised transactions in your account - update your mobile numbers/email IDs with your stockbrokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day.
  • For Depository Transaction 'Prevent Unauthorized Transactions in your demat account - Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day.
  • If you are subscribing to an IPO, there is no need to issue cheques. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.
  • Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
  • Pay 20% or "var + elm" whichever is higher as upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  • Risk disclosures on Derivatives:
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost

  • Advisory - Investors :
  • Ensure that pay-out of funds/securities is received in your account within 1 working day from the date of pay-out.
  • Register for online applications viz Speed-e and Easiest provided by Depositories for online delivery of securities as an alternative to DDPI/POA.
  • Ensure that you receive Contract Notes within 24 hours of your trades and Statement of Account at least once in a quarter from your Stock Broker.
  • If you have opted for running account, please ensure that the stock broker settles your account regularly and in any case not later than 90 days (or 30 days if you have opted for 30 days settlement).
  • Do not keep funds idle with the Stock Broker.
  • Regularly login into your account to verify balances and verify the demat statement received from depositories for correctness.
  • Check messages sent by Exchanges on a monthly basis regarding funds and securities balances reported by the trading member and immediately raise a concern if you notice a discrepancy.
  • Always keep your contact details viz Mobile number / Email ID updated with the stock broker. You may take up the matter with Stock Broker / Exchange if you are not receiving the messages from Exchange / Depositories regularly.
  • If you observe any discrepancies in your account or settlements, immediately take up the same with your stock broker and if the Stock Broker does not respond, with the Exchange/Depositories.
  • Beware of fixed/guaranteed/regular returns/ capital protection schemes. Brokers or their authorized persons or any of their associates are not authorized to offer fixed/guaranteed/regular returns/ capital protection on your investment or authorized to enter into any loan agreement with you to pay interest on the funds offered by you. Please note that in case of default of a member claim for funds or securities given to the broker under any arrangement/ agreement of indicative return will not be accepted by the relevant Committee of the Exchange as per the approved norms.
  • Please do not transfer funds, for the purposes of trading to anyone, including an authorized person or an associate of the broker, other than a SEBI registered Stock broker.

  • As per advisory issued by exchanges, while dealing in options, clients/investors shall avoid the following:
  • Sharing of trading credentials – login id & passwords including OTP’s.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through WhatsApp, Telegram, YouTube, Facebook, SMS, calls, etc.
  • Trading in “Options” based on recommendations from unauthorized / unregistered investment advisors and influencers.

Awareness regarding guidelines of margin collection:
1)Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
2)Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
3)Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.
Issued in the interest of investors

Dear Investor - As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor. https://www.bseipf.com/investors_education.html

Copyright © 2024 Arihant Capital Markets Ltd. All rights Reserved.

Designed,Developed and Content powered by CMOTS Infotech (ISO 9001:2015 certified)

x
  • QR-CodeNew